This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| HLA-B27 | |
|---|---|
| Name | HLA-B27 |
| Organism | Human |
HLA-B27 HLA-B27 is a human leukocyte antigen allele group of the HLA-B locus associated with antigen presentation and autoimmune risk. Identified through serology and molecular typing, it has played a central role in immunogenetics, rheumatology, and transplant medicine. Research tracing antigenic specificity, population genetics, and clinical correlations has linked HLA-B27 with multiple spondyloarthropathies, infectious outcomes, and evolutionary studies.
HLA-B27 was first characterized in studies that also involved researchers connected to institutions such as the Rockefeller University, Johns Hopkins Hospital, Mayo Clinic, University of Oxford, and Karolinska Institutet. Early serological surveys referenced work by figures associated with Jean Dausset and Baruj Benacerraf as part of the broader human leukocyte antigen mapping that included collaborations across National Institutes of Health and European laboratories. Subsequent molecular cloning and structural analyses were advanced at centers like Massachusetts Institute of Technology and EMBL.
HLA-B27 belongs to the HLA class I gene family on chromosome 6 within the Human leukocyte antigen complex region studied by teams at Harvard Medical School and University College London. Allelic diversity—such as B*27:02, B*27:04, B*27:05, B*27:09—was defined by sequencing efforts that referenced methods refined at Sanger Centre and Cold Spring Harbor Laboratory. The encoded heavy chain noncovalently associates with beta-2 microglobulin, a relationship examined in structural biology labs at Max Planck Institute for Biochemistry and Riken. X-ray crystallography from groups related to University of Cambridge revealed the peptide-binding groove architecture that underlies peptide specificity and T cell receptor engagement.
As a class I molecule, HLA-B27 presents endogenous peptides to CD8+ T lymphocytes, a process central to adaptive immunity investigated by researchers affiliated with Pasteur Institute, Weizmann Institute of Science, and Stanford University School of Medicine. Antigen presentation studies have referenced models developed at National Institute of Allergy and Infectious Diseases and peptide-loading pathways elucidated in work involving ETH Zurich. Interactions with natural killer cell receptors and ER aminopeptidases were topics pursued at Karolinska Institutet and Imperial College London, linking HLA-B27 peptide repertoires to viral antigens studied in the context of outbreaks documented by Centers for Disease Control and Prevention and World Health Organization.
HLA-B27 shows strong epidemiological association with ankylosing spondylitis, a connection highlighted in cohorts from Uppsala University Hospital, Addenbrooke's Hospital, and University of Toronto. Associations extend to reactive arthritis outbreaks following infections traced by Centers for Disease Control and Prevention investigations, and to uveitis cases reported in clinics such as Moorfields Eye Hospital. The allele is less strongly linked to psoriatic arthritis and inflammatory bowel disease in studies from Cleveland Clinic and Mayo Clinic, while distinct alleles show variable risk documented by research groups at University of Groningen and University of Sydney.
Proposed mechanisms include arthritogenic peptide presentation described in hypotheses developed in laboratories at University of California, San Francisco and University of Pennsylvania, misfolding and unfolded protein response models advanced by teams at Institut Pasteur and University of Pennsylvania School of Medicine, and homodimer formation theories explored at University of Cambridge and Trinity College Dublin. Molecular mimicry concepts were discussed in relation to pathogens characterized by investigators at Pasteur Institute and NIH, while genetic epistasis involving ERAP1 and ERAP2 was elucidated in studies from Wellcome Sanger Institute and Karolinska Institutet.
Clinical HLA typing employs serology, PCR-SSP, sequence-specific oligonucleotide probing, and next-generation sequencing platforms developed by companies and academic groups associated with Illumina, Thermo Fisher Scientific, and diagnostic laboratories at Mayo Clinic and Johns Hopkins Hospital. Testing is routinely used in rheumatology clinics at institutions such as Royal National Hospital for Rheumatic Diseases and Hospital for Special Surgery to support diagnosis alongside imaging modalities like MRI protocols standardized by collaborators at University of Oxford and Mount Sinai Hospital.
HLA-B27 allele frequencies vary globally, with high prevalence reported among indigenous populations studied at University of Otago and University of Hawaii, elevated frequencies in northern European cohorts from Karolinska Institutet and University of Bergen, and lower prevalence in some East Asian and African populations characterized by projects at Peking University and University of Cape Town. Population genetics research involving the 1000 Genomes Project and the Human Genome Diversity Project informed hypotheses about selective pressures potentially involving infectious disease exposures cataloged by WHO and historical migrations discussed in work at University of Cambridge and Max Planck Institute for Evolutionary Anthropology.
Management strategies integrate nonsteroidal anti-inflammatory drugs, biologic therapies targeting tumor necrosis factor or interleukin pathways developed by pharmaceutical groups linked to Roche, AbbVie, and Pfizer, and physiotherapy programs delivered through centers such as Guy's and St Thomas' NHS Foundation Trust and University Hospital Heidelberg. Prognosis varies with disease phenotype; multidisciplinary clinics at Hospital for Special Surgery, Mayo Clinic, and Karolinska University Hospital provide longitudinal care and outcome data that inform guidelines from professional bodies like the American College of Rheumatology and European League Against Rheumatism.
Category:Immunogenetics